Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $38.57.

A number of brokerages recently issued reports on ZNTL. Wedbush upped their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. HC Wainwright reissued a “buy” rating and issued a $46.00 price target on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th.

Insiders Place Their Bets

In related news, CFO Melissa B. Epperly sold 2,573 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the sale, the chief financial officer now owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Captrust Financial Advisors increased its stake in Zentalis Pharmaceuticals by 15,160.0% during the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock worth $35,000 after purchasing an additional 758 shares during the period. US Bancorp DE increased its stake in Zentalis Pharmaceuticals by 88.7% during the 2nd quarter. US Bancorp DE now owns 887 shares of the company’s stock worth $25,000 after buying an additional 417 shares during the period. Point72 Hong Kong Ltd acquired a new stake in Zentalis Pharmaceuticals during the 1st quarter worth approximately $72,000. China Universal Asset Management Co. Ltd. boosted its position in Zentalis Pharmaceuticals by 132.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock valued at $36,000 after buying an additional 1,030 shares during the period. Finally, Quest Partners LLC acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $38,000.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $12.71 on Thursday. The firm has a market capitalization of $901.90 million, a price-to-earnings ratio of -2.80 and a beta of 1.73. The company’s 50 day simple moving average is $14.04 and its two-hundred day simple moving average is $14.19. Zentalis Pharmaceuticals has a 1-year low of $9.56 and a 1-year high of $31.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.09. On average, equities analysts anticipate that Zentalis Pharmaceuticals will post -3.72 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.